Skip to main content
Article thumbnail
Location of Repository

Ziprasidone in the treatment of mania in bipolar disorder

By Stephen E Nicolson and Charles B Nemeroff


Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). 12,800-mg ziprasidone overdose without signifi cant ECG changes. General Hospital Psychiatry,
  2. (2002). A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
  3. (1978). A diagnostic interview: the schedule for affective disorders and schizophrenia.
  4. (1979). A new depression scale designed to be sensitive to change.
  5. (2004). A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
  6. (1978). A rating scale for mania: reliability, validity and sensitivity.
  7. (2005). A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
  8. (2006). Abilify prescribing information.
  9. (2005). Acute akathisia associated with quetiapine use.
  10. (2004). Adjunctive ziprasidone in bipolar mania: short- and long-term data. 157th annual meeting of the American Psychiatric Association.
  11. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis.
  12. (2005). Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
  13. (2006). Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.
  14. (2001). Bipolar disorder algorithms. TIMA procedural manual.
  15. (2005). Bipolar disorder: quality of life and the impact of atypical antipsychotics.
  16. (2005). Bipolar mixed states and their treatment. Expert Review of Neurotherapeutics,
  17. (2000). Diagnostic and statistical manual of mental disorders, 4th ed, text revision.
  18. (1976). Early clinical drug evaluation manual.
  19. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
  20. (2004). Effi cacy and safety of ziprasidone in bipolar disorder: short- and long-term data. 157th annual meeting of the American Psychiatric Association.
  21. (2006). Emerging treatments for bipolar disorder: safety and adverse effect profi les. Annals of Pharmacotherapy,
  22. (2007). Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
  23. (2006). Extrapyramidal side effects with atypical neuroleptics in bipolar disorder.
  24. (1997). Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses.
  25. (2005). Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Safety,
  26. (1989). Fluoxetineinduced akathisia: clinical and theoretical implications.
  27. (2005). From clinical research to clinical practice: a 4-year review of ziprasidone.
  28. (2007). Geodon prescribing information.
  29. (1981). Hamilton Depression Rating Scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia.
  30. (1988). Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia.
  31. (2003). Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
  32. (2001). Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
  33. (2004). Intravenous ziprasidone for treatment of delirium in the intensive care unit.
  34. (2005). Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients.
  35. (2006). Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis.
  36. (2006). Manic/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases.
  37. (2001). Movement disorders associated with neuroleptic treatment.
  38. (2004). Neuroleptic malignant syndrome and atypical antipsychotic drugs.
  39. (2004). Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clinical Therapeutics,
  40. (2007). Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
  41. (2002). Neuroleptic Malignant Syndrome with ziprasidone.
  42. (1993). Neuroleptic malignant syndrome.
  43. (2004). No signifi cant QTc interval changes with high-dose ziprasidone: a case series.
  44. (2006). Pediatric bipolar disorder: emerging diagnostic and treatment approaches. Child and Adolescent Psychiatric Clinics of North America,
  45. (1986). Persistent tardive dyskinesia in bipolar patients.
  46. (2002). Practice guideline for the treatment of patients with bipolar disorder revision.
  47. (2005). Pregnancy outcome of women using typical antipsychotic drugs: a prospective comparative study.
  48. (2005). Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. General Hospital Psychiatry,
  49. (2002). Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone.
  50. (1989). Risk factors for neuroleptic malignant syndrome. A case-control study.
  51. (2007). Risperdal prescribing information.
  52. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs,
  53. (2004). Selection of atypical antipsychotics for the management of schizophrenia.
  54. (2004). Side effects of atypical antipsychotic drugs. Current Pharmaceutical Design,
  55. (2000). Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.
  56. (1994). Suicide in bipolar disorder in Finland.
  57. (2002). Tardive dyskinesia and ziprasidone.
  58. (2004). Tardive dyskinesia in 2 patients treated with ziprasidone.
  59. (1992). Tardive dyskinesia: a task force report of the American Psychiatric Association.
  60. (1982). Tardive dyskinesia: prevalence and risk factors,
  61. (2000). The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium.
  62. (2005). The highest intentional ziprasidone overdose was not fatal. Acta Psychiatrica Scandinavica,
  63. (2000). The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
  64. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin,
  65. (2002). The reproductive safety profi le of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics.
  66. (1999). The risk of suicide in patients with bipolar disorders.
  67. (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.
  68. (2005). Tolerability profi les of atypical antipsychotics in the treatment of bipolar disorder.
  69. (2006). Torsades de pointes associated with ziprasidone.
  70. (2004). Treatment of bipolar mania with atypical antipsychotics.
  71. (2002). Validation of the behavioral activity rating scale (BARS): a novel measure of activity in agitated patients.
  72. (2004). Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
  73. (2005). Ziprasidone for agitation or psychosis in dementia: four cases.
  74. (2003). Ziprasidone for dementia in elderly patients: case review.
  75. (2005). Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
  76. (2003). Ziprasidone in adjunctive treatment of acute bipolar mania: randomized, double-blind, placebo-controlled trial. 55th Institute on Psychiatric Services Meeting.
  77. (2004). Ziprasidone in bipolar mania: effi cacy across patient subgroups. Presented at the 157th annual meeting of the American Psychiatric Association.
  78. (2003). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
  79. (2004). Ziprasidone monotherapy in pediatric bipolar disorder.
  80. (2005). Ziprasidone overdose: cases recorded in the database of Pfi zer-Spain and literature review.
  81. (2002). Ziprasidone treatment of delirium.
  82. (2006). Ziprasidone- and lithiuminduced neuroleptic malignant syndrome.
  83. (2003). Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Disorders,
  84. (2005). Ziprasidone-induced acute dystonia.
  85. (2006). Ziprasidone-induced acute dystonic reactions in patients with bipolar disorder.
  86. (2003). Ziprasidone-induced oculogyric crisis.
  87. (2005). Ziprasidone-induced tardive dyskinesia.
  88. (2004). Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson’s disease: a diagnostic challenge. Human Psychopharmacology,
  89. (2004). Ziprasidone-related tardive dyskinesia.
  90. (2001). Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profi le.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.